Canine atopic dermatitis (CAD), a skin disorder that is hereditary predisposition to develop pruritic inflammatory skin disease associated with IgE antibodies, which typically target environmental allergens. The disease typically affects dogs aged six months to three years and is characterized by pruritus and secondary skin lesions of a characteristic distribution around the face (mouth, eyes), concave aspect of the ear pinnae, ventral abdomen, flexor aspects of the elbow, carpal, and tarsal joints, interdigital skin, and perineal area. Atopic animals will usually rub, lick, chew, bite, or scratch at their feet, flanks, ears, armpits, or groin, causing patchy or inconsistent hair loss and reddening and thickening of the skin.
COVID-19 scenario analysis:
Pharmaceutical and biotech companies joined with government organizations around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. This brought about 115 vaccine candidates and 155 molecules are in the R&D pipeline. Furthermore, the drugs such as hydroxychloroquinoline which are used for the management of the coronavirus disease-2 has observed rise in demand. The high demand for these drugs has brought up huge opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Due to demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is anticipated to witness a significant growth in the future.
Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis
The major factor which affect the market include the rise in the incidences of atopic dermatitis in dogs triggered due to air pollution and allergens, and is expected to propel the growth in the forecast period. The increase in the demand for the pet insurances and surge in the concern among the pet owners are projected to boost the industry. Furthermore, rise in the R&D investments product launches for canine atopic dermatitis, and the stronger product pipeline for such products would help the industry to grow in the coming years. Additionally, the increase in number of insurances is anticipated to help the industry grow. The rise in strict regulations to restrict off-label usage of human drugs for animals would help the industry flourish. The rise in the number of veterinary practitioner, hospitals and clinics are anticipated to help the industry flourish. Moreover, the stringent regulations over the therapeutics may hinder the market growth.
New product advancements to flourish the market
In May 2017, Ceva launched canine atopic dermatitis product. The product Ceva Animal Health has extended its companion animal dermatology range with the release of Dermipred for the management of pruritus and skin inflammation in cases of canine atopic dermatitis.
In June 2017, Zoetis had launched Cytopoint (lokivetmab), a novel once-monthly injectable treatment for the clinical signs of atopic dermatitis in dogs and the first monoclonal antibody (mAb) therapy approved in the European Union for veterinary use.
Surge in mergers and acquisitions to boost the market
In April 2019, Aratana Therapeutics, a pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats, announced that it had signed an agreement to be acquired by Elanco Animal Health, its global collaboration partner on GALLIPRANT (grapiprant tablets). In conjunction with the transaction, Elanco also announced the formation of a commercial team dedicated to the veterinary specialty business.
In September 2018, LEO Pharma and JW Pharmaceutical had signed a global out-licensing agreement for an atopic dermatitis drug candidate. Per licensing agreement, LEO Pharma will gain exclusive rights to develop and commercialize the JW Pharmaceutical’s new atopic dermatitis product JW601.
Key benefits of the report:
- This study presents the analytical depiction of the global Canine Atopic Dermatitis industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global market share.
- The current market is quantitatively analyzed to highlight the global market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed global market analysis based on competitive intensity and how the competition will take shape in coming years.
Questions answered in the Canine Atopic Dermatitis Market research report:
- Who are the leading market players active in the Canine Atopic Dermatitis market?
- What are the current trends will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities in the market?
- What are the projections for the future that would help in tasking further strategic steps?
Canine Atopic Dermatitis Market Report Highlights
| Aspects | Details |
 By Drug Class |
|
 By Mode of Prescription |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Nextmune, Ceva, AB Science, Vetoquinol UK Ltd, Elanco, Kinderd Biosciences, Boehringer Ingelheim, Zoetis, Toray Industries, Virbac |
 Other Players | Bioceltix |
Loading Table Of Content...
